Table 2.
Clinical trials of epigenetic drugs alone used in solid tumors (1100 cases).
| Tumor type | Year | Patient number | CR | PR | SD | PD | ORR |
|---|---|---|---|---|---|---|---|
| Epithelial ovarian or primary peritoneal carcinoma | 2008 | 24 | 0 | 1 | 9 | 14 | 1 |
| Melanoma | 2014 | 32 | 0 | 2 | 16 | 14 | 2 |
| Multiply solid tumors | 2008 | 55 | 0 | 0 | 14 | 41 | 0 |
| NSCL | 2004 | 47 | 0 | 3 | 14 | 30 | 3 |
| Soft tissue sarcoma | 2013 | 35 | 0 | 0 | 7 | 28 | 0 |
| Multiply solid tumors | 2012 | 36 | 0 | 0 | 6 | 30 | 0 |
| Refractory solid tumors | 2012 | 39 | 0 | 1 | 9 | 29 | 0 |
| Thymic epithelial tumors | 2011 | 41 | 0 | 2 | 25 | 14 | 2 |
| Multiply solid tumors | 2013 | 92 | 0 | 1 | 8 | 83 | 1 |
| Hepatocellular carcinoma | 2012 | 42 | 0 | 10 | 19 | 13 | 10 |
| Multiply solid tumors | 2001 | 53 | 0 | 1 | 3 | 49 | 1 |
| Hepatocellular carcinoma | 2009 | 66 | 0 | 0 | 0 | 66 | 0 |
| Multiply solid tumors | 2006 | 31 | 0 | 0 | 1 | 30 | 0 |
| Multiply solid tumors | 2011 | 24 | 0 | 0 | 5 | 19 | 0 |
| Pleural mesothelioma | 2015 | 73 | 0 | 0 | 2 | 71 | 0 |
| Breast cancer | 2013 | 29 | 0 | 0 | 4 | 25 | 0 |
| Multiply solid tumors | 2009 | 18 | 0 | 0 | 9 | 9 | 0 |
| Gastrointestinal cancer | 2013 | 20 | 0 | 0 | 7 | 13 | 0 |
| Thyroid Carcinoma | 2009 | 19 | 0 | 0 | 9 | 10 | 0 |
| NSCL | 2009 | 14 | 0 | 1 | 7 | 6 | 1 |
| Breast cancer | 2008 | 14 | 0 | 4 | 4 | 6 | 4 |
| Advanced solid tumors | 2013 | 19 | 0 | 0 | 11 | 8 | 0 |
| Head and neck cancer | 2012 | 14 | 0 | 0 | 2 | 12 | 0 |
| Neuroendocrine Carcinoma | 2011 | 8 | 0 | 1 | 4 | 3 | 1 |
| platinum resistant epithelial ovarian cancer and micro papillary (LMP) ovarian tumors | 2010 | 32 | 0 | 1 | 10 | 21 | 1 |
| NSCLC | 2011 | 45 | 1 | 1 | 10 | 24 | 2 |
| refractory advanced cancer | 2007 | 26 | 0 | 0 | 2 | 12 | 0 |
| advanced malignant pleural mesothelioma | 2009 | 18 | 0 | 2 | 4 | 7 | 2 |
| NSCLC | 2013 | 8 | 0 | 0 | 1 | 33 | 0 |
| Head and neck cancer | 2008 | 9 | 0 | 0 | 3 | 6 | 0 |
| Multiply solid tumors | 2008 | 16 | 0 | 0 | 8 | 8 | 0 |
| Mesothelioma | 2014 | 5 | 0 | 0 | 1 | 4 | 0 |
| Multiply solid tumors | 2013 | 28 | 0 | 0 | 9 | 19 | 0 |
| Multiply solid tumors | 2011 | 33 | 0 | 0 | 10 | 23 | 0 |
| Total | 1065 | 1 | 32 | 263 | 81814 | 34 | |
| Response ratio (100%) | 0.1 | 0.03 | 0.24 | 0.73 | 0.03 |
CR, complete response; PR, partial response; SD, stable disease; PD, progressive, disease; ORR (CR + PR), objective response ratio. Response identification based on. Response Evaluation Criteria In Solid Tumors (RECIST). (See references in supplementary file).